endonuclease

Cap-dependent endonuclease-IN-1 is a highly potent, orally active cap-dependent endonuclease inhibitor with antiviral activity for studying influenza virus infection.

PFM39 is a selective MRE11 nucleic acid exonuclease inhibitor and Mirin analog that prolongs mitosis.PFM39 inhibits HR and alleviates repair defects caused by EXO1/BLM depletion.

PFM01 is an inhibitor of MRE11 endonuclease. PFM01 can regulate double-strand break repair (DSBR) by nonhomologous end-joining (NHEJ) versus homologous recombination (HR).

Baloxavir (S-033447) is a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit.

CRT0044876 (7-NO2-ICA) is a potent and selective APE1 inhibitor with IC50 of ~3 μM.

ERCC1-XPF-IN-2 is active in nucleotide excision repair, cisplatin enhancement and γH2AX assays. ERCC1-XPF-IN-2 is a potent inhibitor of ERCC1-XPF endonuclease with an IC 50 value of 0.6 μM [1].

E3330 is a potent and selective APE1(Ref-1) inhibitor, which suppressed NF-kappa B DNA-binding activity.

FEN1-IN-4 (FEN1 Inhibitor C2) is an inhibitor of human flap endonuclease-1 (hFEN1)

Cap-dependent endonuclease-IN-27 (Compound 8) is an orally active cap-dependent endonuclease (CEN) inhibitor. It serves as an antiviral agent with activity against influenza B virus. Additionally, Cap-dependent endonuclease-IN-27 inhibits the polymerase of IFV A/WSN/33 (H1N1) with an EC50 of 12.26 nM.

PAN endonuclease-IN-2 (compound T-31) is a PAN endonuclease inhibitor (IC50: 0.15 μM) and has antiviral properties with broad-spectrum anti-influenza activity. PAN, as the N-terminal PA subunit of the polymerase-RNA complex, possesses a cap-dependent endonuclease (CEN) active site, facilitating RNA cleavage and initiating the synthesis of new RNA molecules. PAN endonuclease-IN-2 targets both influenza HA and RdRp complexes, thereby disrupting viral entry into host cells and impeding viral replication.

Cap-dependent endonuclease-IN-28 (Compound 11) is a potent inhibitor of Cap-dependent endonuclease (CEN). It effectively inhibits the CEN of TOSV, ANDV, and LACV viruses, with IC50 values of 2.4, 0.5, and 4 μM, respectively.

pUL89 Endonuclease-IN-1 (Compound 13d), with an IC50 of 0.88 μM, is a potent inhibitor of human cytomegalovirus (HCMV) pUL89 endonuclease, demonstrating significant antiviral activity [1].

Cap-dependent endonuclease-IN-26, a potent inhibitor of cap-dependent endonuclease (CEN) with an IC50 of 286 nM, exhibits significant antiviral activity against a broad spectrum of influenza A and B strains [1].

pUL89 Endonuclease-IN-2 (Compound 15k) is a highly effective inhibitor of the pUL89 endonuclease of human cytomegalovirus (HCMV), demonstrating potent antiviral activities with an IC50 of 3.0 μM [1].

Cap-dependent endonuclease-IN-25 is a macrocyclic pyridoxal derivative and a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN) with potential for studying viral infections caused by viruses of the Orthomyxoviridae family.

Cap-dependent endonuclease-IN-6 (compound 13) is a Cap-dependent endonuclease (CEN) inhibitor that targets and inhibits the influenza virus.

Cap-dependent endonuclease-IN-19, a spirocyclic pyridinone derivative, is a potent inhibitor of cap-dependent nucleic acid endonuclease (CEN) and effectively inhibits the RNA polymerase activity of influenza A virus.

Cap-dependent endonuclease-IN-13 is a potent inhibitor of cap-dependent endonuclease (CEN) and demonstrates research potential against influenza virus infection [influenza A only].

Cap-dependent endonuclease-IN-10 is a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN), effectively inhibiting influenza viruses with low cytotoxicity, good in vivo pharmacokinetic and pharmacodynamic properties, and good hepatic microsomal stability. It has shown investigational potential against viral infections, including influenza A, B, and C.

Cap-dependent endonuclease-IN-11 is a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN) with demonstrated research potential for treating viral infections.

Cap-dependent endonuclease-IN-21 is a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN) and demonstrates inhibitory effects on influenza virus replication, showing research potential against influenza virus infection (influenza A).

Cap-dependent endonuclease-IN-23 is a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN) and effectively inhibits influenza virus replication, demonstrating significant research potential for influenza virus infection (influenza A).

Cap-dependent endonuclease-IN-5 is a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN) with significant influenza virus inhibitory activity, demonstrating lower cytotoxicity and improved in vivo pharmacokinetic and pharmacodynamic properties.

Cap-dependent endonuclease-IN-14 is a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN) and can inhibit the replication of influenza viruses, showing potential for treating viral infections caused by influenza viruses.